Since no previous X-ray structure of midazolam has been reported, the present study was aimed at determining the conformation of the API and establishing the nature of the interaction between the salt components. The preparation method of 1 was based on a previous report. 4 Colorless, prismatic crystals of 1 precipitated from a solution of pH 3.75 containing midazolam·HCl (45 mg/ml), propylene glycol (23%v/v), glycerol (23%v/v), sodium saccharin (30 mg/ml) and water.
Elemental analysis (averages of triplicate determinations) yielded %C 58.5, %H 3.6, %N 11.0 (calcd. for
C18H14ClFN3
+ ·C7H4NO3S -%C 58.99, %H 3.56, %N 11.01). DSC analysis of 1 yielded an enthalpy of fusion of 49.0 kJ/mol with melting onset and peak temperatures of 183.0 and 189.7˚C respectively.
Intensity data were measured from a crystal of size 0.09 × 0.18 × 0.18 mm, cooled in a stream of nitrogen vapor at 113±2 K. The structure was solved by direct methods and refined by full-matrix least-squares on F 2 using SHELXL-97. All hydrogen atoms were located in difference Fourier maps and were added at idealized positions with Uiso set at 1.2-times those of their parent atoms.
All of the latter were treated anisotropically. Crystal data and refinement details are listed in Table 1 . Final coordinates and equivalent thermal parameters are given in Table 2 .
The X-ray analysis indicates that salt formation involves the transfer of a proton from N25 of the saccharin molecule to the basic centre, N8, of the midazolam molecule ( that the atoms N6, C10, N12 and C13 of the seven-membered ring of the midazolam cation are nearly coplanar, and that the ring adopts a quasi-'boat' conformation with methylene carbon atom C11 forming the 'prow' and atoms C5 and C14 the 'stern'. The symmetry of the ring approaches Cs, as observed in related molecule, 1-(2-bromo-5-methoxyphenyl)-8-chloro-6-(2-fluorophenyl)-4H-1,2,4-triazolo[4,3-a] [1, 4] benzodiazepine, whose molecular parameters for common residues are very similar to those in 1. 5 The fluorophenyl ring plane is significantly twisted out of the average plane of the tricyclic fused ring system (Table 3) , its orientation being stabilized by an intermolecular H-bond, C15-H·F22 i (i = x, 1/2-y, 1/2+z) with C·F 3.176(3)Å. The least-squares plane through the nine ring atoms of the saccharinate moiety yields an average deviation of 0.028(2)Å, with a maximum of 0.067(1)Å for atom S24.
Despite the presence of aromatic rings in both components, no π-stacking interactions with ring centroid separations significantly less than 3.7 Å are observed in the crystal. However, a complex network of H-bonds stabilises the crystal structure. In addition to those already mentioned, each sulfonyl O atom of the saccharinate ion engages in C-H·O hydrogen bonding (C23-H·O34 ii , ii = 1-x, 1-y, -z, with C·O 3.326(3)Å, and C29-H·O35 iii , iii = 1-x, 1-y, -1-z, with C·O 3.276(3)Å). Finally, atom N25 of the saccharinate moiety is an acceptor of a hydrogen bond, C9-H·N25 iv (iv = -x, 1-y, -z, with C·N 3.340(3)Å).
The X-ray analysis thus confirms that compound 1 is a salt, indicating also the specific proton transfer involved in its formation. Conformational parameters for the midazolam cation are reported for the first time. Extensive hydrogen bonding in the crystal of 1 no doubt contributes to its unusually low solubility relative to many other drug saccharinates. Ueq = (1/3)ΣiΣjUij(ai*aj*)(ai·aj). Fig. 2 ORTEP drawing of the title structure at the 50% probability level. Table 3 Selected bond distances (Å), and angles (°)
